{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T14:40:18Z","timestamp":1767624018478,"version":"3.48.0"},"reference-count":46,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Consejo Superior de Investigaciones Cient\u00edficas of Spain","award":["201920E022"],"award-info":[{"award-number":["201920E022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular dysplasia characterized by recurrent epistaxis, anemia, and visceral arteriovenous malformations. Epistaxis is the most frequent and disabling manifestation, with limited effective pharmacological options. Propranolol, a non-selective beta-blocker with vasoconstrictive and antiangiogenic properties, has shown benefit in other vascular anomalies but remains scarcely studied in HHT. This study aimed to evaluate the effect of oral propranolol on nasal bleeding in patients with HHT. Methods: A retrospective observational study including 151 adults with HHT (44 treated with propranolol, 107 untreated) was conducted using data from an Institutional HHT Registry from a referral center. Baseline demographic and clinical variables were recorded. Outcomes at 6 months included changes in hemoglobin, adherence to nasal hygiene, use of bleeding-related therapies, and improvement in epistaxis frequency and intensity according to the Sadick\u2013Bergler scale. Logistic regression models were adjusted for confounders and indication bias using inverse probability of treatment weighting (IPTW). Results: After IPTW adjustment, propranolol was significantly associated with reduced frequency of epistaxis (adjusted OR: 3.8; 95% CI: 1.3\u201311.2; p = 0.016), while no effect was observed on intensity. Hemoglobin levels increased modestly in both groups without a significant difference. Patients without propranolol showed greater antifibrinolytic use, whereas adherence to nasal care remained stable among treated patients. Conclusions: Oral propranolol reduced nasal bleeding frequency in HHT, even among patients with greater baseline severity. Given its accessibility, safety, and potential to lessen treatment burden, it may represent a valuable adjunct therapy. This study represents the largest cohort of HHT patients treated with propranolol reported to date. Randomized trials including standardized bleeding scores and patient-reported outcomes are warranted to confirm clinical and quality-of-life benefits.<\/jats:p>","DOI":"10.3390\/jcm15010372","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:53:50Z","timestamp":1767610430000},"page":"372","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Propranolol Reduces Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Large Retrospective Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-9503","authenticated-orcid":false,"given":"Marcelo Mart\u00edn","family":"Serra","sequence":"first","affiliation":[{"name":"HHT Unit, Argentine Rendu Study Group (ARG), Internal Medicine Department, Hospital Italiano de Buenos Aires, Buenos Aires C1199ABB, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanina","family":"Pagotto","sequence":"additional","affiliation":[{"name":"Argentine Rendu Study Group (ARG), Research Department, Hospital Italiano de Buenos Aires, Buenos Aires C1199ABB, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-2245","authenticated-orcid":false,"given":"Luisa Maria","family":"Botella","sequence":"additional","affiliation":[{"name":"Center for Biological Research \u201cMargarita Salas\u201d, Spanish National Research Council (CSIC), 28040 Madrid, Spain"},{"name":"Spanish National Network for Research on Rare Diseases (CIBERER), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1563-6162","authenticated-orcid":false,"given":"Carmelo","family":"Bernabeu","sequence":"additional","affiliation":[{"name":"Center for Biological Research \u201cMargarita Salas\u201d, Spanish National Research Council (CSIC), 28040 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/jmg.2009.069013","article-title":"International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia","volume":"48","author":"Faughnan","year":"2011","journal-title":"J. Med. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-024-00585-z","article-title":"Hereditary haemorrhagic telangiectasia","volume":"11","author":"Hermann","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","first-page":"221","article-title":"Prevalence of hereditary hemorrhagic telangiectasia in a medical care program organization in Buenos Aires, Argentina","volume":"84","author":"Serra","year":"2024","journal-title":"Medicina"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2796.1999.00398.x","article-title":"Hereditary haemorrhagic telangiectasia: A population-based study of prevalence and mortality in Danish patients","volume":"245","author":"Kjeldsen","year":"1999","journal-title":"J. Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/14728222.2017.1365839","article-title":"Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia","volume":"21","author":"Rossi","year":"2017","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E591","DOI":"10.1002\/ajh.24832","article-title":"The Brain Vascular Malformation Consortium HHT Investigator Group. Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia","volume":"92","author":"Kasthuri","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41436-020-0775-8","article-title":"Cura\u00e7ao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2)","volume":"22","author":"McDonald","year":"2020","journal-title":"Genet. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2020008739","article-title":"Hereditary hemorrhagic telangiectasia: Systemic therapies, guidelines, and an evolving standard of care","volume":"137","year":"2021","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4193\/Rhino09.138","article-title":"Altered quality of life in Rendu-Osler-Weber disease related to recurrent epistaxis","volume":"49","author":"Ingrand","year":"2011","journal-title":"Rhinology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12955-017-0586-z","article-title":"Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT)","volume":"15","author":"Zarrabeitia","year":"2017","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4193\/Rhin16.315","article-title":"Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young\u2019s procedure: A 22-year experience","volume":"55","author":"Lund","year":"2017","journal-title":"Rhinology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.7326\/L21-0067","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia","volume":"174","author":"Faughnan","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_14","unstructured":"Mager, H.J., Bernabeu, C., and Post, M. (2021). Hereditary Hemorrhagic Telangiectasia: Recent Advances and Future Challenges, MDPI."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13023-019-1281-4","article-title":"Future treatments for hereditary hemorrhagic telangiectasia","volume":"15","author":"Robert","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104587","DOI":"10.1016\/j.phrs.2019.104587","article-title":"\u03b2-blockers: Their new life from hypertension to cancer and migraine","volume":"151","author":"Fumagalli","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"Hubiche","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1542\/peds.2008-3458","article-title":"Propranolol for severe infantile hemangiomas: Follow-up report","volume":"124","author":"Sans","year":"2009","journal-title":"Pediatrics"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cuesta, A.M., Gallardo-Vara, E., Casado-Vela, J., Recio-Poveda, L., Botella, L.-M., and Albi\u00f1ana, V. (2022). The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084217"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Albi\u00f1ana, V., Gallardo-Vara, E., de Rojas-P, I., Recio-Poveda, L., Aguado, T., Canto-Cano, A., Aguirre, D.T., Serra, M.M., Gonz\u00e1lez-Peramato, P., and Mart\u00ednez-Pi\u00f1eiro, L. (2020). Targeting \u03b22-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092740"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1160\/TH11-11-0809","article-title":"Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia","volume":"108","author":"Zarrabeitia","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/coa.12821","article-title":"Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: Retrospective, then prospective study, in a total of 21 patients","volume":"42","author":"Contis","year":"2017","journal-title":"Clin. Otolaryngol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/lary.27930","article-title":"Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis","volume":"129","author":"Encinas","year":"2019","journal-title":"Laryngoscope"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.21037\/ajo-24-64","article-title":"A randomised, double-blind, placebo-controlled trial of oral propranolol for hereditary haemorrhagic telangiectasia","volume":"8","author":"Liaw","year":"2025","journal-title":"Aust. J. Otolaryngol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/000348940211100306","article-title":"Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia","volume":"111","author":"Bergler","year":"2002","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1542\/peds.2012-1691","article-title":"Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference","volume":"131","author":"Drolet","year":"2013","journal-title":"Pediatrics"},{"key":"ref_28","first-page":"525","article-title":"Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells","volume":"103","author":"Zarrabeitia","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/19458924221118131","article-title":"The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review","volume":"36","author":"Albarki","year":"2022","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/CH-211253","article-title":"TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT)\u2014Study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial","volume":"80","author":"Andorfer","year":"2021","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mei-Zahav, M., Gendler, Y., Bruckheimer, E., Prais, D., Birk, E., Watad, M., Goldschmidt, N., and Soudry, E. (2020). Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103130"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez, C., Gonzalez, M.L., Ferraris, A., Bandi, J.C., and Serra, M.M. (2020). Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228486"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0042-1743467","article-title":"Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians","volume":"48","year":"2022","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.anl.2015.12.001","article-title":"Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia","volume":"43","author":"Ichimura","year":"2016","journal-title":"Auris Nasus Larynx"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40463-017-0235-x","article-title":"Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia\u2014A preliminary report","volume":"46","author":"Blau","year":"2017","journal-title":"J. Otolaryngol. Head. Neck Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11986","DOI":"10.1038\/s41598-019-48502-9","article-title":"Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial","volume":"9","author":"Pitiot","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jamaoto.2020.3025","article-title":"Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial","volume":"146","author":"Peterson","year":"2020","journal-title":"JAMA Otolaryngol. Head. Neck Surg."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Albi\u00f1ana, V., Cuesta, A.M., de Rojas-P, I., Gallardo-Vara, E., Recio-Poveda, L., Bernab\u00e9u, C., and Botella, L.M. (2020). Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061766"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41433-021-01863-w","article-title":"Retina Evidence Trials InterNational Alliance (R.E.T.I.N.A.) Study Group. The clinician\u2019s guide to p values, confidence intervals, and magnitude of effects","volume":"36","author":"PhillPhillips","year":"2022","journal-title":"Eye"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Andorfer, K.E.C., Zeman, F., Koller, M., Zeller, J., Fischer, R., Seebauer, C.T., Vielsmeier, V., Bohr, C., and K\u00fchnel, T.S. (2022). TIMolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (TIM-HHT)-A Prospective, Randomized, Double-Blind, Controlled, Cross-Over Trial. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112335"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Arthur, H.M., and Roman, B.L. (2022). An update on preclinical models of hereditary haemorrhagic telangiectasia: Insights into disease mechanisms. Front. Med., 9.","DOI":"10.3389\/fmed.2022.973964"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kaulanjan-Checkmodine, P., Oucherif, S., Prey, S., Gontier, E., Lacomme, S., Loot, M., Miljkovic-Licina, M., Cario, M., L\u00e9aut\u00e9-Labr\u00e8ze, C., and Taieb, A. (2022). Is Infantile Hemangioma a Neuroendocrine Tumor?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23095140"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: A European cross-over controlled trial in a rare disease","volume":"12","author":"GaillGaillard","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/pde.12239","article-title":"Long-term treatment with oral propranolol reduces relapses of infantile hemangiomas","volume":"31","author":"Giachetti","year":"2014","journal-title":"Pediatr. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"bcr2013203056","DOI":"10.1136\/bcr-2013-203056","article-title":"Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: A look at CYP2D6 metabolising variants","volume":"2014","author":"Epperla","year":"2014","journal-title":"BMJ Case Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/1\/372\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:14:13Z","timestamp":1767611653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/1\/372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15010372"],"URL":"https:\/\/doi.org\/10.3390\/jcm15010372","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]}}}